Sulfonate Groups and Saccharides as Essential Structural Elements in Heparin-Mimicking Polymers Used as Surface Modifiers: Optimization of Relative Contents for Antithrombogenic Properties
- 27 December 2017
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 10 (1) , 1440-1449
Abstract
Blood compatibility is a long sought-after goal in biomaterials research, but remains an elusive one, and in spite of extensive work in this area, there is still no definitive information on the relationship between material properties and blood responses such as coagulation and thrombus formation. Materials modified with heparin-mimicking polymers (HMP) have shown promise, and indeed may be seen as comparable to materials modified with heparin itself. In this work, heparin was conceptualized as consisting of two major structural elements: saccharide-containing and sulfonate-containing units, and polymers based on this concept were developed. Copolymers of 2-methacrylamido glucopyranose, containing saccharide groups, and sodium 4-vinylbenzenesulfonate, containing sulfonate groups, were graft-polymerized on polyurethane (PU) surfaces by free radical polymerization. This graft polymerization method is simple, and the saccharide and sulfonate contents are tunable by regulating the feed ratio of the monomers. Homopolymer grafted materials, containing only sulfonate or saccharide groups, showed different effects on cell-surface interactions including platelet adhesion, adhesion and proliferation of vascular endothelial cells and adhesion and proliferation of smooth muscle cells. The copolymer grafted materials showed effects due to both sulfonate and saccharide elements with respect to blood responses, and the optimum composition was obtained at a 2:1 ratio of sulfonate to saccharide units (material designated PU-PS1M1). In cell adhesion experiments this material showed the lowest platelet and human umbilical vein smooth muscle cell (HUVSMC) density, and the highest human umbilical vein endothelial cell (HUVEC) density. Among the materials investigated PU-PS1M1 also had the longest plasma clotting time. This material was thus shown to be multifunctional with a combination of properties suggesting thromboresistant behavior in blood contact.Keywords
Funding Information
- Natural Sciences and Engineering Research Council of Canada
- National Natural Science Foundation of China (21334004, 21474071, 21774089)
- Jiangsu Province
- Priority Academic Program Development of Jiangsu Higher Education Institutions
This publication has 48 references indexed in Scilit:
- Substrate-Independent Robust and Heparin-Mimetic Hydrogel Thin Film Coating via Combined LbL Self-Assembly and Mussel-Inspired Post-Cross-linkingACS Applied Materials & Interfaces, 2015
- Heparan sulfate chains potentiate cadmium cytotoxicity in cultured vascular endothelial cellsArchives of Toxicology, 2014
- Progress in heparin and heparin-like/mimicking polymer-functionalized biomedical membranesJournal of Materials Chemistry B, 2014
- Blood compatible materials: state of the artJournal of Materials Chemistry B, 2014
- Immobilization of heparin/poly-l-lysine nanoparticles on dopamine-coated surface to create a heparin density gradient for selective direction of platelet and vascular cells behaviorActa Biomaterialia, 2014
- Heparin-functionalized polymeric biomaterials in tissue engineering and drug delivery applicationsActa Biomaterialia, 2014
- Surface modification of cardiovascular materials and implantsSurface and Coatings Technology, 2013
- Conjugation of Basic Fibroblast Growth Factor on a Heparin Gradient for Regulating the Migration of Different Types of CellsBioconjugate Chemistry, 2013
- The role of heparin binding surfaces in the direction of endothelial and smooth muscle cell fate and re-endothelializationBiomaterials, 2012
- Thrombin Binds to Soluble Fibrin Degradation Products Where it Is Protected From Inhibition by Heparin-Antithrombin but Susceptible to Inactivation by Antithrombin-Independent InhibitorsCirculation, 1998